Regencell Bioscience Holdings Ltd

Healthcare US RGC

16.371USD
-1.029(5.91%)

Last update at 2025-07-10T18:50:00Z

Day Range

16.4018.83
LowHigh

52 Week Range

3.1630.49
LowHigh

Fundamentals

  • Previous Close 17.40
  • Market Cap65.06M
  • Volume943564
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.98054M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.45

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -6.06233M -7.59455M -1.34675M -0.81237M -0.39099M
Minority interest 0.19M 0.15M - - -
Net income -5.87113M -7.42273M -1.34675M -0.81237M -0.39099M
Selling general administrative 4.43M 5.08M 0.94M 0.31M 0.16M
Selling and marketing expenses 0.26M 0.03M 0.00158M 0.11M 0.00364M
Gross profit - - - - -
Reconciled depreciation 0.77M 0.60M 0.03M 0.00952M 0.00000M
Ebit -6.27367M -7.61777M -1.38136M -0.81237M -0.39099M
Ebitda -5.50398M -7.01337M -1.35491M -0.80285M -0.39099M
Depreciation and amortization 0.77M 0.60M 0.03M 0.00952M -
Non operating income net other - - - - -
Operating income -6.27367M -7.61777M -1.38136M -0.81237M -0.39099M
Other operating expenses 6.27M 7.62M 1.38M 0.81M 0.39M
Interest expense - 0.02M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.19120M -0.17183M -0.03462M - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 6.27M 7.62M 1.38M 0.81M 0.39M
Cost of revenue - - - - -
Total other income expense net 0.21M 0.02M 0.03M - -
Discontinued operations - - - - -
Net income from continuing ops -6.06233M -7.59455M -1.34675M -0.81237M -0.39099M
Net income applicable to common shares - -7.44594M -1.34675M -0.81237M -0.39099M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 12.62M 18.02M 0.34M 0.51M 0.24M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 0.03M 0.00744M - -
Total liab 0.63M 0.94M 4.34M 3.16M 2.08M
Total stockholder equity 12.03M 17.07M -3.99764M -2.65089M -1.83852M
Deferred long term liab - - 0.17M - -
Other current liab 0.17M 0.17M 0.66M 0.10M -
Common stock 0.00013M 0.00013M 0.00010M 0.00010M 0.00010M
Capital stock 0.00013M 0.00013M 0.00010M 0.00010M 0.00010M
Retained earnings -17.31507M -11.44394M -3.99799M -2.65125M -1.83888M
Other liab - - - - -
Good will - - - - -
Other assets - 0.11M 0.19M 0.02M -
Cash 1.56M 6.42M 0.06M 0.39M 0.24M
Cash and equivalents - - - - -
Total current liabilities 0.61M 0.58M 4.34M 3.16M 2.08M
Current deferred revenue - - - - -
Net debt -1.10113M -5.64574M 3.62M 2.68M 1.84M
Short term debt 0.44M 0.41M 3.68M 3.07M 2.08M
Short long term debt - - 3.68M 3.07M 2.08M
Short long term debt total 0.46M 0.77M 3.68M 3.07M 2.08M
Other stockholder equity 29.43M 28.51M 0.00026M 0.00026M 0.00026M
Property plant equipment - 1.46M 0.08M 0.11M -
Total current assets 11.62M 16.44M 0.07M 0.39M 0.24M
Long term investments - - - - -
Net tangible assets - 17.07M -3.99764M -2.65089M -1.83852M
Short term investments 10.00M 10.00M - - -
Net receivables 0.06M 0.03M 0.00744M - -
Long term debt - - - - -
Inventory - -0.02760M -0.00744M - -
Accounts payable - - - - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.08666M - - -0.00952M -
Additional paid in capital - - - - -
Common stock total equity - - - 0.00010M 0.00010M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.11M 0.11M 0.19M 0.02M -
Deferred long term asset charges - - - - -
Non current assets total 1.00M 1.57M 0.27M 0.13M 0.00000M
Capital lease obligations 0.46M 0.77M - - -
Long term debt total - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 0.06M -10.00000M -10.00000M -0.11784M -10.00000M
Change to liabilities - 0.00000M 0.00000M 0.00000M 0.00000M
Total cashflows from investing activities - -10.78088M -10.78088M -0.11784M -0.11784M
Net borrowings - -0.43197M 0.61M 0.99M 0.48M
Total cash from financing activities 0.13M 22.41M 0.44M 0.99M 0.48M
Change to operating activities - -1.02407M 0.55M 0.08M 0.08M
Net income -6.06233M -7.59455M -1.34675M -0.81237M -0.39099M
Change in cash -4.85220M 6.36M -0.32757M 0.14M 0.09M
Begin period cash flow 6.42M 0.06M 0.39M 0.24M 0.15M
End period cash flow 1.56M 6.42M 0.06M 0.39M 0.24M
Total cash from operating activities -4.96295M -5.26706M -0.76731M -0.72657M -0.39099M
Issuance of capital stock 0.00000M 22.67M - - -
Depreciation 0.77M 0.60M 0.03M 0.00952M 0.00952M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.13M -0.26797M 0.44M -0.11784M 0.48M
Change to netincome - 2.60M 2.75M 2.75M 2.75M
Capital expenditures 0.03M 0.78M 0.78M 0.12M 0.12M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.50894M -1.02407M 0.55M 0.08M 0.00000M
Stock based compensation 0.92M 2.76M - - -
Other non cash items -0.08540M -0.01073M - - -
Free cash flow -4.99034M -6.04793M -0.76731M -0.84441M -0.39099M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
RGC
Regencell Bioscience Holdings Ltd
-1.029 5.91% 16.37 - - - 4.12 -6.9909
ZTS
Zoetis Inc
0.31 0.19% 158.58 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR
0.59 2.25% 26.81 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
- -% 134.09 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR
-0.32 2.12% 14.81 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

Profile

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Regencell Bioscience Holdings Ltd

Chinachem Leighton Plaza, Causeway Bay, Hong Kong

Key Executives

Name Title Year Born
Mr. Yat-Gai Au Founder, Chairman & CEO 1973
Ms. Michelle Chan Financial Controller NA
Mr. Wai Hong Chung COO & Chief Strategy Officer 1977
Dr. Yi-Chung Chao Ph.D. Chief Medical Officer & Director 1964
Mr. Tien Hsiang Chau Exec. Officer 1970
Dr. Yi-Chung Chao Ph.D. Special Advisor & Director 1964
Mr. Tien Hsiang Chau Executive Officer 1970
Ms. Antonia Assang Senior Vice President of Project Management NA
Mr. Yat-Pui Au Chief Business Officer 1974

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.